EVALUATION OF SOME PHARMACEUTICAL FORMULATIONS OF LISINOPRIL THROUGH DISSOLUTION TESTING

  • Madalina VIERIU ”Gr.T. Popa” University of Medicine and Pharmacy Iași
  • Nela BIBIRE ”Gr.T. Popa” University of Medicine and Pharmacy Iași
  • M. APOSTU ”Gr.T. Popa” University of Medicine and Pharmacy Iași
  • Cristina TOCU Antibiotice S.A. Iași
  • V. DORNEANU ”Gr.T. Popa” University of Medicine and Pharmacy Iași
  • Cristina VLASE Antibiotice S.A. Iași
Keywords: LISINOPRIL, TABLETS, DISSOLUTION TEST

Abstract

Aim: Lisinopril is a drug of the angiotensin
converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension,
congestive heart failure, heart attacks and also in preventing renal and retinal complications
of diabetes. We compared the dissolution profiles of Lisinopril 20 mg tablets (Antibiotice
S.A. Iaºi) and Zestril 20 mg tablets (Astra Zeneca). Material and method: Because lisinopril
is a third class active substance, we performed dissolution tests in standard media at three pH
values: 1.2, 4.5 and 6.8 using the paddle apparatus at 75 rpm. Results: Both pharmaceutical
formulations present a dissolution percentage more than 85% (Q) of the labeled amount.
Conclusion: Both pharmaceutical formulations present similar dissolution profile.

Author Biographies

Madalina VIERIU, ”Gr.T. Popa” University of Medicine and Pharmacy Iași

School of Pharmacy
Department of Analytical Chemistry

Nela BIBIRE, ”Gr.T. Popa” University of Medicine and Pharmacy Iași

School of Pharmacy
Department of Analytical Chemistry

M. APOSTU, ”Gr.T. Popa” University of Medicine and Pharmacy Iași

School of Pharmacy
Department of Analytical Chemistry

Cristina TOCU, Antibiotice S.A. Iași

Center for Drug Evaluation

V. DORNEANU, ”Gr.T. Popa” University of Medicine and Pharmacy Iași

School of Pharmacy
Department of Analytical Chemistry

Cristina VLASE, Antibiotice S.A. Iași

Center for Drug Evaluation

References

1. Cristea AN. Tratat de farmacologie. Bucureºti : Ed. Medicalã, 2005.
2. *** Analytical Profiles of Drug Substances and Excipients (vol 21). New York: Academic Press Inc., 1992.
3. *** The United States Pharmacopeia 29. Rockville: The United States Pharmacopeial Convention, 2005.
4. Shin MC, Kim JK, Kim CK. Bioequivalence evaluation of two brands of lisinopril tablets by in vitro
comparative dissolution test and in vivo bioequivalence test. Arzneim Forsch 2008; 58 (1): 11-17.
5. Sagirli O, Ersoy L. An HPLC method for the determination of lisinopril in human plasma and
urine with fluorescence detection. J Chromatogr B 2004; 809 (1): 159-165.
6. Qin W, Zhang Z, Tian Y, Xu F, Wang N, Chen Y. Rapid quantification of lisinopril in human plasma
by liquid chromatography/tandem mass spectrometry. Biomed Chromatogr 2007; 21 (4): 415-421.
7. Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS. Effect of the combination
of lisinopril and hydrochlorothiazide on the bioequivalence of tablet formulations. Arzneim Forsch
2004; 54 (9A): 605-610.
8. *** H.C.S. al A.N.M. referitoare la aprobarea Ghidului privind investigarea biodisponibilitãþii ºi
bioechivalenþei nr. 54/15.12.2006.
9. *** Note for Guidance on the Investigation of Bioavailability and Bioequivalence, CPMP/EWP/
QWP/1401/98 : 2002.
Published
2019-11-14